
Targeting peptide G-protein coupled receptors (GPCRs) for novel drug development
Modern GPCR drug development is encumbered by a lack of information about the molecular structure underlying GPCR function and the reliance on cell-based assays that are prone to false positives in drug screening.
Aims
Projects are available on multiple GPCR targets with training in various techniques.
The largest single class of drug targets is the G Protein-Coupled Receptor (GPCR) family, which were targets for 13 of the top 50 prescription drugs sold in the USA in 2010 (26%).
While the past 10 years have seen advances in our knowledge of GPCR structures peptide GPCRs, especially those with large structured ectodomains (ECDs), remain poorly understood. This is mainly because the flexibility of linkers joining the ECDs to the transmembrane domains (TMDs) impedes crystallization. Hence the study of complex peptide receptors requires different approaches.
Our laboratory targets peptide GPCRs for drug development utilizing state-of-the-art molecular pharmacology, biochemical and nuclear magnetic resonance (NMR) techniques. These techniques enable us to map the native peptide binding sites of these receptors and determine the mechanisms of receptor activation as well their cell signalling characteristics.
A complete understanding of the mechanism of ligand binding and activation is required to design drugs targeting these receptors. Furthermore we are utilizing novel techniques to study the receptor structures (see project below) and are also studying ligand interactions with receptor domains using soluble receptor domains and NMR (A/Prof Gooley, Bio21).
These studies are complemented by peptide drug development projects and small molecule screening projects with collaborators. Additionally, we are working with pharmaceutical industry partners (e.g. Takeda and Novartis to facilitate drug development efforts).
Recent Publications:
1. Sethi A, Bruell S, Patil N, Hossain MA, Scott DJ, Petrie EJ, Bathgate RAD*, Gooley PR* (2016) The complex binding mode of the peptide hormone H2 relaxin to its receptor RXFP1. Nature Communications, 7: 11344
2. Bruell S, Sethi A, Smith N, Scott DJ, Hossain MA, Wu Q-P, Guo Z-Y, Petrie EJ, Gooley PR, Bathgate RAD (2017) Distinct activation modes of the Relaxin Family Peptide Receptor 2 in response to insulin-like peptide 3 and relaxin. Scientific Reports 7: 3294
3. Diepenhorst NA, Petrie EJ, Chen CZ, Wong A, Hossain MA, Bathgate RAD*, Gooley PR* (2015) Investigation of interactions at the extracellular loops of the relaxin family peptide receptor 1 (RXFP1). Journal of Biological Chemistry, 289: 34938-34952
4. Kong RCK, Petrie EJ, Mohanty B, Ling J, Lee JCY, Gooley PR and Bathgate RAD (2013) RXFP1 utilises hydrophobic moieties on a signalling surface of the LDLa module to mediate receptor activation. Journal of Biological Chemistry 288: 28138-28151
5. Bathgate RAD, Halls ML, Van der Westhuizen ET, Callander GE, Kocan M and Summers RJ (2012) Relaxin Family Peptides and Their Receptors. Physiological Reviews. 93: 405–480
Latest Florey news for drug development
-
Addiction, Alzheimer’s Disease, Anxiety, Autism, Behaviour, Bipolar disorder, Brain injury, Cancer, Cardiovascular disease, Dementia, Depression, Epigenetics, Epilepsy, Huntington’s disease, Imaging, Mental Health, Multiple sclerosis, Parkinson’s, Schizophrenia, Stroke, STEM
Another role for the oxytocin in the brain – and this time it has nothing to do with love or trust
Oxytocin is well known for its role as the ‘trust hormone’, as well as aiding delivery and breast feeding when babies are born, but is less well known for its role in regulating the body’s fluid levels and saltiness.
-
Addiction, Alzheimer’s Disease, Anxiety, Autism, Behaviour, Bipolar disorder, Brain injury, Cancer, Cardiovascular disease, Dementia, Depression, Epigenetics, Epilepsy, Huntington’s disease, Imaging, Mental Health, Multiple sclerosis, Parkinson’s, Schizophrenia, Stroke, STEM
Using the relaxin hormone to treat Asthma - an intriguing possibility
A modified form of the Relaxin hormone developed by Florey scientists appears to be safe, cheap to manufacture and has significant anti-fibrotic capabilities, which could have major implications for treating fibrotic diseases like asthma and heart disease.
Support us
Brain health affects all Australians. You can support our research by making a donation or a bequest.
- Give todayDonate now
- Pledge over timeJoin our brains trust
- Plan for the futureMake a gift in your will
Newsletter
Latest breakthroughs, news, events & more.